ARTICLE | Product Development
AstraZeneca’s vaccine results suggest a modality-independent dip in protection against variants
Plus AZ-Oxford vaccine to be tested in combo with Pfizer-BioNTech’s Comirnaty and Russian vaccine Sputnik V
February 6, 2021 2:56 AM UTC
AstraZeneca is the latest company to report that its COVID-19 vaccine seems to be working against new variants of the virus, just not quite as well. So far, that effect has been independent of the vaccine modality.
The latest data analysis from the COV002 U.K. pivotal trial of COVID-19 AstraZeneca (AZD1222), the adenoviral vector vaccine developed by AstraZeneca plc (LSE:AZN; NASDAQ:AZN), revealed only a small decline in protection against an emerging SARS-CoV-2 variant. ...